Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Gross Margin (2016 - 2025)

Historic Gross Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 53.37%.

  • Protalix BioTherapeutics' Gross Margin changed 0.0% to 53.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.54%, marking a year-over-year increase of 216700.0%. This contributed to the annual value of 54.46% for FY2024, which is 104500.0% down from last year.
  • Protalix BioTherapeutics' Gross Margin amounted to 53.37% in Q3 2025, which was down 0.0% from 62.51% recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Gross Margin high stood at 82.47% for Q2 2023, and its period low was 15.54% during Q4 2023.
  • Its 5-year average for Gross Margin is 52.67%, with a median of 53.37% in 2025.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Gross Margin tumbled by -569800bps in 2021, and later surged by 631200bps in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Gross Margin (Quarter) stood at 63.18% in 2021, then increased by 14bps to 72.18% in 2022, then crashed by -78bps to 15.54% in 2023, then skyrocketed by 406bps to 78.67% in 2024, then plummeted by -32bps to 53.37% in 2025.
  • Its last three reported values are 53.37% in Q3 2025, 62.51% for Q2 2025, and 19.11% during Q1 2025.